2. Immunology/Inflammation
  3. COX
  4. Rebamipide

レバミピド  (Synonyms: Rebamipide; OPC12759; Proamipide)

製品番号: HY-B0360 純度: 99.74%
COA 取扱説明書 Technical Support

Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 90098-04-7

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 27 在庫あり
Solution
10 mM * 1 mL in DMSO USD 27 在庫あり
Solid
500 mg $25 在庫あり
1 g $40 在庫あり
5 g $80 在庫あり
10 g   お問い合わせ  
50 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

Other Forms of Rebamipide:

レバミピド 関連抗体

Top Publications Citing Use of Products

    Rebamipide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132.  [Abstract]

    H&E staining of skin sections revealed that rebamipide treatment increased dermal thickness, hair bulb size, and hair shaft elongation compared to the control group. Ki67 immunofluorescent staining revealed enhanced cellular proliferation in the hair bulbs of Rebamipide-treated mice. Nuclei were stained with DAPI.

    Rebamipide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132.  [Abstract]

    Western blot analysis of autophagy-related proteins in telogen-phase skin of mice treated with 3% Rebamipide for 7 days.

    Rebamipide purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2025 Oct 18;26(20):10132.  [Abstract]

    Immunofluorescent staining of LC3 in the dermal white adipose tissue (dWAT) layer of the dorsal skin treated with 3% Rebamipide for 7 days to assess autophagy activation.

    COX アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    COX COX-1 COX-2 COX-3

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer[1][2].

    IC50 & Target[1]

    COX-2

     

    体外実験

    Rebamipide (1.4, 2.7, 5.4 mM; 24 h) inhibits proliferation of gastric cancer cell[1].
    Rebamipide (5.4 mM; 30 min) activates Smad signaling pathway in AGS cells[1].
    Rebamipide (5.4 mM; 3 h) induces the expression of Cdk inhibitor p21 in AGS cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    レバミピド 関連抗体

    Cell Proliferation Assay[1]

    Cell Line: AGS cells
    Concentration: 1.4, 2.7, 5.4 mM
    Incubation Time: 24 h
    Result: Significant decreased in cell proliferation in a concentration-dependent manner.

    Western Blot Analysis[1]

    Cell Line: AGS cells
    Concentration: 5.4 mM
    Incubation Time: 30 min or 3 h
    Result: Significantly increased phosphorylation of Smad2/3 by 1.2-fold when at 30 min and formation of Smad2/3-Smad4 complex by 1.4-fold.
    Upregulated expression of p21 protein by 2.5-fold when at 3 h.
    体内実験

    Rebamipide (5, 15, 50 mg/kg; p.o.; once daily for 14 days) enhances the expression of COX-2 and PGE2, and protects gastric mucosa from acid-induced injury in rat gastric mucosa[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Specific pathogen-free male Sprague-Dawley rats (200-230 g; 7-week-old)[2].
    Dosage: 5, 15, 50 mg/kg
    Administration: Oral administration; once daily for 14 days.
    Result: Increased the level of COX-2 immunoreactivity and PGE2 in a dose-dependent manner. (PGE2 is implicated in protection of gastric mucosa from various insults and acceleration of gastric wound healing).
    Inhibited intragastric HCl administration-induced gastric mucosal bleeding and erosion.
    臨床実験
    分子量

    370.79

    分子式

    C19H15ClN2O4
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC(C(NC(C1=CC=C(Cl)C=C1)=O)CC(C2=CC=CC=C2N3)=CC3=O)=O
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 25 mg/mL (67.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.6969 mL 13.4847 mL 26.9694 mL
    5 mM 0.5394 mL 2.6969 mL 5.3939 mL
    10 mM 0.2697 mL 1.3485 mL 2.6969 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (6.74 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (6.74 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  50% PEG300    50% Saline

      Solubility: 10 mg/mL (26.97 mM); Suspended solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.74%

    COA (251 KB) HNMR (183 KB) LCMS (103 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.6969 mL 13.4847 mL 26.9694 mL 67.4236 mL
    5 mM 0.5394 mL 2.6969 mL 5.3939 mL 13.4847 mL
    10 mM 0.2697 mL 1.3485 mL 2.6969 mL 6.7424 mL
    15 mM 0.1798 mL 0.8990 mL 1.7980 mL 4.4949 mL
    20 mM 0.1348 mL 0.6742 mL 1.3485 mL 3.3712 mL
    25 mM 0.1079 mL 0.5394 mL 1.0788 mL 2.6969 mL
    30 mM 0.0899 mL 0.4495 mL 0.8990 mL 2.2475 mL
    40 mM 0.0674 mL 0.3371 mL 0.6742 mL 1.6856 mL
    50 mM 0.0539 mL 0.2697 mL 0.5394 mL 1.3485 mL
    60 mM 0.0449 mL 0.2247 mL 0.4495 mL 1.1237 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Rebamipide Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Rebamipide90098-04-7OPC12759 ProamipideOPC 12759OPC-12759COXCyclooxygenasegastric cancerPGE2COX-2mucosal protectiongastroduodenal ulcergastritisAGS cellsInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Rebamipide
    製品番号:
    HY-B0360
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.